Microbix Biosystems Inc. (MBX) — closed signal from December 5, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 5, 2026.
Predicted vs. what happened
What happened
Reached its target in 40 days.
The thesis — published December 5, 2025
Microbix could bounce higher because the company can buy back up to 5% of its shares and a deal with Seegene Mexico should help HPV test sales. Recent trading shows lots more people buying than usual and very bullish sentiment, which can push the price up fast. But low trading volume and reports of a fund selling shares mean be cautious with position size.
Primary drivers
- Company can repurchase up to 5% of shares, reducing supply
- Recent buying momentum is strong, which can lift price quickly
- Seegene Mexico deal should boost HPV testing sales
- Low trading volume and fund exits make the stock more volatile
How it played out
MBX: target reached in 40 days
Lyra published MBX at 30.99 on 2025-12-05 with a short-term thesis for 38% growth. The thesis pointed to a buyback of up to 5% of shares, stronger recent buying momentum, a Seegene Mexico deal that was expected to help HPV test sales, and volatility risk from low trading volume and reported fund exits.
Inside the window, MBX reached the 42.76 target in 40 days. It peaked at 44.89 on 2026-01-15, with a peak gain of 44.9%. By 2026-03-05, it ended at 31.44. The thesis played out on the target, even though the close gave back most of the move.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.